A Phase 2, Randomized, Multicenter, Open-Label Safety Study of ISAtx247 and Cyclosporine (NEORAL) in Post Renal Transplant

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/016/11/03

Funding

  • Isotechnika Inc: $35,433.00